Sonus heads north to ATL territory

Article

Ultrasound contrast agent developerSonus Pharmaceuticals is moving its corporate headquarters thismonth. The move, to the Seattle suburb of Bothell, WA, will makeSonus a close neighbor of ultrasound company ATL, also based inBothell. Sonus previously

Ultrasound contrast agent developerSonus Pharmaceuticals is moving its corporate headquarters thismonth. The move, to the Seattle suburb of Bothell, WA, will makeSonus a close neighbor of ultrasound company ATL, also based inBothell.

Sonus previously was headquartered in Costa Mesa, CA. The company,founded by Omniscan inventor Dr. Steven Quay, is developing aline of intravascular ultrasound contrast agents.

The company's first agent, EchoGen, is based on an emulsionthat turns into echogenic microbubbles when injected (SCAN 1/19/94).Sonus filed an investigational new drug (IND) application forEchoGen earlier this year.

The ATL and Sonus facilities are located within a stone's throwof each other, according to ATL president David Perozek. WhileATL and Sonus employees can look forward to sharing the sunnyskies for which the Pacific Northwest is famous, the relationshipbetween the companies will go no farther than that, at least forthe time being.

ATL and Sonus do not have a business relationship and haveno plans to develop one in the near future, Perozek said.

Sonus representatives were not available for comment.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.